BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Endovasc Inc. (EVSC) Issues Update On Angiogenix; Cease Funding Research By Its Subsidiary, Angiogenix Limited, Inc.


10/19/2005 5:09:46 PM

MONTGOMERY, Texas--(BUSINESS WIRE)--May 25, 2005--Endovasc Inc. (OTCBB: EVSC), announced today that the Company will cease funding research by its subsidiary, Angiogenix Limited, Inc. and that Angiogenix has terminated its licensing agreement with Leland J. Stanford University dated February 1, 2000 relating to the use of a nicotine receptor agonist (NRA). Endovasc's Board of Directors cite two reasons for the decision: firstly, ceasing research efforts for Angiogenix will allow the Company to concentrate its resources on funding future clinical studies for Liprostin, and secondly, the current licensing agreement contained unrealistic deadlines for the commercialization of NRA. According to Diane Dottavio, "Endovasc has clearly been focusing its attention and capital resources toward furthering Liprostin's clinical development. Having recently completed a promising international Phase II FDA study, we feel it is in the best interest of the Company to dedicate the majority of its resources Liprostin to make this drug available to the many patients suffering from PAOD who currently have limited treatment options."

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->